Congestive Heart Failure Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra

DelveInsight's "Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Congestive Heart Failure Market Share @ Congestive Heart Failure Market Outlook- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Congestive Heart Failure Market Report
• In April 2025, AskBio Inc., announced a study of phase 2 study to evaluate the safety and efficacy of a single dose of AB-1002, administered via antegrade intracoronary artery infusion, in males and females age >18 years with non-ischemic cardiomyopathy and NYHA Class III symptoms of HF.
• The analysis of Congestive Heart Failure in the 7MM draws a clear scenario which showed that the patients with HFpEF have a larger proportion (i.e., ~50%) because the heart is not severely affected but keeps on working through medication or symptomatic treatment, whereas, in the case of HFrEF, the patient's heart is majorly affected. With growing age, the pumping rate of the heart declines.
• In 2023, among all the four New York Heart Association (NYHA) Classes of heart failure, Class II accounted for around 45% of the total diagnosed heart failure cases in the 7MM.
• Maximum cases of heart failure fall in the age group of ≥ 60 years. In 2023, approximately 6.8 million cases of heart failure in the US belonged to this age group.
• In 2023, among EU4 and the UK, the largest number of heart failure cases were observed in Germany, followed by France and Spain, whereas the United Kingdom accounted for the smallest number of cases in the 7MM.
• The increase in Congestive Heart Failure Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Congestive Heart Failure Market is anticipated to witness growth at a considerable CAGR.
• The leading Congestive Heart Failure Companies such as Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company and others.
• Promising Congestive Heart Failure Pipeline Therapies such as KW-3902IV, Relaxin, GSK716155, Furosemide, Torsemide, Bumetanide, Dapagliflozin, Tolvaptan, Nesiritide and others.

Stay ahead in the Congestive Heart Failure Therapeutics Market with DelveInsight's Strategic Report @ Congestive Heart Failure Market Outlook- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Congestive Heart Failure Epidemiology Segmentation in the 7MM
The epidemiology section of Congestive Heart Failure offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total Diagnosed Prevalent Cases of Heart Failure
• Gender-specific Cases of Heart Failure
• Ejection Fraction-specific Cases of Heart Failure
• NYHA Class-specific Cases of Heart Failure
• Type-specific Cases of Heart Failure (Acute and Chronic)
• Age-specific Cases of Heart Failure

Download the report to understand which factors are driving Congestive Heart Failure Epidemiology trends @ Congestive Heart Failure Prevalence- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Congestive Heart Failure drugs
• ENTRESTO: Novartis
ENTRESTO combines a neprilysin inhibitor and an angiotensin II receptor blocker. In July 2015, the US FDA approved sacubitril with valsartan to reduce the risk of cardiovascular (CV) death and hospitalization in patients with Congestive Heart Failure (NYHA Class II-IV) associated with reduced ejection fraction and got expanded approval in October 2019 and February 2021 for pediatric patients aged ≥1 with symptomatic heart failure with systemic left ventricular systolic dysfunction and adult patients with Congestive Heart Failure respectively. ENTRESTO captured the major share of the Congestive Heart Failure market in 2022.

• JARDIANCE: Boehringer Ingelheim and Eli Lilly
JARDIANCE is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. The candidate is also being investigated in pivotal trials for heart failure post myocardial infarction and chronic kidney disease. In June 2021, Boehringer Ingelheim and Eli Lilly and Company announced that the European Commission had granted marketing authorization for JARDIANCE (empagliflozin) as a treatment for adults with symptomatic chronic HFrEF. Later in August 2021, it was approved by the US FDA. US FDA had granted Breakthrough Therapy designation based on results from the Phase III EMPEROR-Preserved trial. In the last year, JARDIANCE grabbed regulatory approval from all the major regulatory bodies (FDA, EMA, and PMDA) for the treatment of chronic heart failure in patients with HFpEF, thereby extending its targeted niche.

Emerging Congestive Heart Failure drugs
• KERENDIA (finerenone): Bayer
Finerenone (BAY 94-8862) is an investigational novel, nonsteroidal, selective mineralocorticoid receptor antagonist (MRA) that has been shown to block many harmful effects of mineralocorticoid receptor (MR) overactivation, which is a major driver of kidney and heart damage. The drug has received regulatory approval in the US, Canada, and the EU to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes. The drug is currently in a Phase III FINEARTS-HF trial in patients with heart failure and left ventricular ejection fraction greater or equal to 40%. FINEARTS-HF is currently the largest outcome trial investigating an MRA in HFpEF.

MOUNJARO (tirzepatide): Eli Lilly and Company
Tirzepatide (LY3298176) is a once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of both incretins into a single novel molecule. In May 2022, tirzepatide was approved by the US FDA as a treatment for adults with type 2 diabetes. Currently, the drug is in the Phase III stage of the clinical development program evaluating its safety and efficacy in participants with HFpEF and obesity. This drug has true potential and is expected to garner the maximum revenue by 2034.

To learn more about Congestive Heart Failure treatment guidelines, visit @ Congestive Heart Failure Treatment Market Landscape- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Congestive Heart Failure Drugs Market Insights
The primeval drug classes like ACE inhibitors, ARBs, beta-blockers, and diuretics are still at the forefront of the heart failure treatment space. Furthermore, off-label usage of other therapies such as aldosterone antagonists, amiodarone, antiaggregants, anticoagulants, calcium antagonists, and nitrates, are also high in patients affected by heart failure. The majority of therapies are prescribed in combination, and beta-blockers are one of the most prescribed classes. Among the approved therapies, ENTRESTO is Novartis' one of the most important drugs, and its revenue is expected to rise in the next few years. At present, ENTRESTO leads the Congestive Heart Failure market among the approved therapies. After a slow beginning, ENTRESTO has emerged as one of Novartis' most important growth drivers. With the current approval in preserved ejection fraction, ENTRESTO is getting bigger and better.

Major Congestive Heart Failure Companies
Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company and others.

Congestive Heart Failure Market Outlook
After a scarcity of sustainable new therapies for more than a decade, new classes of agents for the treatment of patients with Congestive Heart Failure were approved by the US FDA - ENTRESTO (sacubitril/valsartan), a combined angiotensin receptor-neprilysin inhibitor (ARNI) and CORLANOR (ivabradine), a sinoatrial node modulator. Both drugs are recommended for use as part of a comprehensive medical therapy regimen. Recently approved VERQUVO (vericiguat), from Merck Pharma, in January 2021 is the newest addition for treating heart failure.

Congestive Heart Failure Drugs Uptake
The drug chapter of the Congestive Heart Failure report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of Congestive Heart Failure clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Congestive Heart Failure.

Learn more about the FDA-approved drugs for Congestive Heart Failure @ Drugs for Congestive Heart Failure Treatment- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Congestive Heart Failure Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Congestive Heart Failure Companies- Otsuka Pharmaceutical, Cytokinetics, AstraZeneca, Mesoblast, Bayer, Novo Nordisk, Lexicon Pharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, Eli Lilly and Company and others.
• Congestive Heart Failure Pipeline Therapies- KW-3902IV, Relaxin, GSK716155, Furosemide, Torsemide, Bumetanide, Dapagliflozin, Tolvaptan, Nesiritide and others.
• Congestive Heart Failure Market Dynamics: Congestive Heart Failure Market Drivers and Barriers
• Congestive Heart Failure Market Access and Reimbursement, Unmet Needs and Future Perspectives, Congestive Heart Failure Clinical Trials

Discover more about Congestive Heart Failure Drugs in development @ Congestive Heart Failure Clinical Trials Assessment- https://www.delveinsight.com/sample-request/congestive-heart-failure-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Congestive Heart Failure Executive Summary
3. Congestive Heart Failure Competitive Intelligence Analysis
4. Congestive Heart Failure: Market Overview at a Glance
5. Congestive Heart Failure: Disease Background and Overview
6. Patient Journey
7. Congestive Heart Failure Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Congestive Heart Failure Unmet Needs
10. Key Endpoints of Congestive Heart Failure Treatment
11. Congestive Heart Failure Marketed Products
12. Congestive Heart Failure Emerging Therapies
13. Congestive Heart Failure: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Congestive Heart Failure Market Outlook
16. Access and Reimbursement Overview of Congestive Heart Failure
17. KOL Views
18. Congestive Heart Failure Market Drivers
19. Congestive Heart Failure Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Pulmonary emphysema market- https://www.delveinsight.com/report-store/pulmonary-emphysema-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
HIP Replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Sepsis market_ https://www.delveinsight.com/report-store/sepsis-market-insight
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Coronary stents market- https://www.delveinsight.com/report-store/stents-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
India:- +91-9650213330

This release was published on openPR.